Diagnosis of Structural Heart Disease Using MCG
- Conditions
- Structural Heart Abnormality
- Registration Number
- NCT06315998
- Lead Sponsor
- Qilu Hospital of Shandong University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> - Those with suspected structural heart disease who are scheduled to undergo<br> echocardiography or cardiac magnetic resonance. Structural heart disease includes<br> cardiomyopathy (hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive<br> cardiomyopathy, etc.), congenital heart disease (including ventricular septal<br> defect, atrial septal defect, patent ductus arteriosus, Tetralogy of Fallot)<br> syndrome, tricuspid valve malformation, etc.), valvular heart disease (aortic valve<br> stenosis, mitral valve stenosis, etc.), ventricular remodeling caused by myocardial<br> ischemia or cardiac structural changes.<br><br> - Signed the consent form.<br><br>Exclusion Criteria:<br><br> - Those with atrial fibrillation, supraventricular tachycardia, atrioventricular block<br> and other arrhythmias that have not returned to normal;<br><br> - Those who are thought to be incapable of completing the relevant examinations by an<br> attending physicians (or physicians with higher qualifications) due to unstable<br> clinical conditions, metal implants, etc., or those who are unable to perform the<br> examinations;<br><br> - Those with obvious abnormal thyroid function, severe anemia or other blood diseases<br> and other diseases that obviously affect the circulating blood supply;<br><br> - Those with malignant tumors;<br><br> - Pregnant or lactating women.
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The efficacy of the MCG in identifying structural heart disease
- Secondary Outcome Measures
Name Time Method